reduce insulin dose when starting glp-1 receptor agonist Evolution of GLP‐1 Agonists for Diabetes Treatment A Comprehensive Review of the
Description
Chiquette E, Toth PP, Ramirez G, Cobble M, Chilton R: Treatment with exenatide once weekly or twice daily for 30 weeks is associated with changes in several cardiovascular risk markers

& Lau, J

Tirzepatide's dual-agonist mechanism provides superior glycemic control with HbA1c reductions of 1.5-2.4%, compared to 1.2-1.8% for single-agonist alternatives
Notably, injection site reactions demonstrated significantly higher incidence in the adult cohort compared to geriatric patients (p 100 kg